Across TCGA pan-cancer cohorts, LRIG2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRIG2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LRIG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRIG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where LRIG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.186	0.682	.003	24	view →
UCEC	DFS	Median	All	0.964	0.824	.006	14	view →
LUAD	OS	Median	II,III,IV	0.141	0.709	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LRIG2 tumor-vs-normal RNA expression · all LRIG2 data types